

Godrej Agrovet Limited

Registered Office -

Godrej One, 3rd Floor,
Pirojshanagar, Eastern Express Highway,
Vikhroli (East) Mumbai- 400079. India

Tel: +91-22-25188010/8020/8030

Fax: +91-22-25195124

Email: gavlho@godrejagrovvet.com

Website: www.godrejagrovvet.com

CIN : L15410MH1991PLC135359

Date: August 5, 2026

To,

BSE Limited

P. J. Towers, Dalal Street,
Fort, Mumbai – 400001

To,

National Stock Exchange of India Limited

Exchange Plaza, Bandra - Kurla Complex,
Bandra (East), Mumbai - 400051

Ref.: BSE Scrip Code No. "540743"

Ref.: "GODREJAGRO"

Sub: Media Release

Dear Sir / Madam,

The Board of Directors of Godrej Agrovet Limited ("The Company") at its Meeting held today, i.e., on **Wednesday, August 5, 2026**, has approved the Standalone and Consolidated Unaudited Financial Results for the Quarter ended June 30, 2026.

We enclose herewith a copy of the Media Release and the same is being placed on the website of the Company i.e., www.godrejagrovvet.com.

Kindly take the above on your record.

Thanking you,

Yours sincerely,

For Godrej Agrovet Limited

Vivek Raizada

Head- Legal & Company Secretary & Compliance Officer

(ACS 11787)

Encl.: As above



PRESS RELEASE

Mumbai, August 5, 2026: Godrej Agrovet Limited ("GAVL") has today announced its financial results for the first quarter ended June 30, 2026.

HIGHLIGHTS OF FINANCIAL PERFORMANCE

Q1 FY27 Financial Summary

- The Consolidated Sales was Rs. 2,852 crore in Q1 FY27 as compared to Rs. 2,603 crore in Q1 FY26.
- Profit before tax*, excluding non-recurring items, of Rs.172 crore in Q1 FY27 as compared to Rs. 188 crore in Q1 FY26.

** Profit before tax excludes share of profit from Joint Venture*

MANAGING DIRECTOR'S COMMENTS

Commenting on the performance, Mr. Sunil Kataria, Chief Executive Officer & Managing Director, Godrej Agrovet Limited, said:

Godrej Agrovet Limited delivered a resilient performance in Q1 FY27, with consolidated sales reporting double-digit growth despite operating in a challenging environment marked by delayed monsoon conditions and geopolitical tensions that led to inflationary pressures. While profitability was impacted by temporary cost headwinds in select businesses, we remain confident of our ability to navigate these challenges through operational excellence and focused cost management.

The quarter was characterized by robust volume-led growth across majority of our businesses. Animal Nutrition delivered another standout quarter, with ~15% growth in cattle feed volumes and improved realizations driving strong revenue momentum, while disciplined execution across sourcing, cost management and operating leverage translated to margin expansion. Our Bangladesh joint venture, ACI Godrej Agrovet, also returned to a strong growth path, delivering healthy volume and profitability growth.

The Oil Palm business continued to deliver strong performance, with improved realizations and enhanced oil extraction efficiency driving robust growth in both revenue and profitability, while Fresh Fruit Bunch (FFB) volumes remained resilient against a high base despite delayed monsoon conditions.



Astec LifeSciences continued to make strong progress on its turnaround journey, achieving another quarter of EBITDA break-even and significantly reducing losses, driven by improved volumes, better realizations, and higher capacity utilization.

The Crop Care business was impacted by a significantly delayed monsoon, slower kharif sowings following one of the driest June in over a decade, affecting volumes of our in-house cotton herbicide; however, strong market traction and continued scale-up of Ashitaka (a new Maize herbicide) reaffirmed the strength of our innovation-led portfolio diversification efforts, helping to partially mitigate the impact even as lower cotton herbicide volumes weighed on margins. The Dairy business continued to strengthen its value-added portfolio, delivering healthy revenue growth backed by strong volume growth and increasing the share of value-added products from 42% to 49% of sales. However, industry-wide milk inflation and war impact on other inputs impacted profitability. In Godrej Foods, branded volumes continued to grow strongly in line with our strategic direction and the business maintained stable revenues. Profitability was affected by higher input costs and inflationary pressure from geopolitical disruptions.

The significant improvement in net working capital over the past two years reflects our disciplined focus on capital allocation, cash generation and value creation. As we progress through FY27, we remain focused on building a customer and market centric organization with sharp execution focus to build a stronger higher return portfolio.

SEGMENT-WISE BUSINESS HIGHLIGHTS

Animal Nutrition

- Delivered robust topline growth powered by strong demand-led volume expansion and improved realizations. Cattle feed volumes grew ~15% YoY, reinforcing the business's leadership position and growth momentum.
- Margin performance strengthened materially, with underlying segment results improving by ~36% YoY, reflecting the benefits of strategic commodity sourcing, operating leverage, and relentless cost discipline.

Oil Palm

- Segment revenue was driven by improved realizations and higher sales volumes. Fresh fruit bunch (FFB) volumes remained broadly flat despite high-comparable base in Q1FY26, which had benefited from the early onset of the monsoon.
- Segment result increased YoY, supported by enhanced oil extraction efficiency and higher realizations.



Crop Care (Standalone)

- Demand remained muted amid delayed monsoon progress and slower kharif sowings following one of the driest June in over a decade. Consequently, there was a de-growth in segment revenue predominantly due to lower volumes of in-house cotton herbicide.
- The Company's strategic diversification journey has started on a strong footing, with Ashitaka (Maize Herbicide) and Takai (Paddy insecticide) gaining strong market traction. The successful scale-up of these recent launches reinforces the innovation-led growth strategy and helped partially mitigate the impact of adverse market conditions during the quarter.
- The significant reduction in volumes as stated above resulted in margin contraction, with segment margin declining in Q1 FY27.

Astec LifeSciences

- Astec LifeSciences sustained its recovery momentum in Q1FY27, reporting substantial improvement in EBITDA over Q1FY26, driven by margin expansion across both Enterprise and CDMO categories. Building on the operational turnaround achieved in FY26, the business performance reflects the success of turnaround initiatives taken and positions the business for sustained profitability and growth.
- There was a marginal de-growth in revenue primarily due to change in product mix.

Dairy

- The Dairy business delivered healthy revenue growth in Q1FY27 compared to Q1FY26, primarily driven by strong volume growth in value-added products, reflecting sustained consumer demand and brand strength across key categories. Salience of value-added products improved from 42% in Q1FY26 to 49% in Q1FY27.
- Q1 FY27 EBITDA was impacted by elevated milk procurement prices amid industry-wide constraints in milk availability, together with war-led inflation in certain other inputs. Management remains focused on calibrated pricing actions, procurement efficiencies and cost optimization to mitigate these near-term pressures.



Godrej Foods Limited (GFL)

- Branded volume salience grew ~ 6% YoY in Q1FY27, underscoring sustained execution against the Company's value-accretive branded growth strategy. This helped to offset the impact of deliberate reduction in live bird volumes, enabling Godrej Foods Ltd. (GFL) to deliver stable revenues while further improving the quality of earnings.
- EBITDA margins in Q1FY27 moderated due to higher input costs and inflationary pressure from geopolitical disruptions. While the company implemented calibrated pricing actions, the increase in costs could only be partially mitigated.

ACI Godrej Agrovet Private Limited, Bangladesh

- ACI GAVL demonstrated a strong comeback and has firmly returned to growth trajectory, delivering robust topline growth in the quarter driven predominantly by broad-based volume expansion across categories.
- PBT increased YoY by 12% driven by operational leverage and volume growth. Profit after tax declined YoY primarily due to the impact of higher effective tax rate following the change in the applicable tax rate from 15% to 27.5% with effect from July 1, 2025. The impact is primarily tax-related and does not reflect any deterioration in the operating performance of the business.

- ENDS -



About Godrej Agrovet Limited

Godrej Agrovet Limited (GAVL) is a diversified, Research & Development focused agri-business Company, dedicated to improving the productivity of Indian farmers by innovating products and services that sustainably increase crop and livestock yields. GAVL holds leading market positions in the different businesses in which it operates - Animal Nutrition, Crop Care, Oil Palm, Dairy and Poultry and Processed Foods.

GAVL has a pan India presence with sales of over a million tons annually of high-quality animal feed. Our teams have worked closely with Indian farmers to develop large Oil Palm Plantations which is helping in bridging the demand and supply gap of edible oil in India. In the crop protection segment, the company meets the niche requirement of farmers through innovative agrochemical offerings. GAVL, through its subsidiary Astec Life Sciences Limited, is also a business-to-business (B2B) focused bulk manufacturer of fungicides & herbicides. In Dairy and Poultry and Processed Foods, the company operates through its subsidiaries Creamline Dairy Products Limited and Godrej Tyson Foods Limited. Apart from this, GAVL also has a joint venture with the ACI group of Bangladesh for animal feed business in Bangladesh.

For more information on the Company, please log on to www.godrejagrovet.com.

For further information, please contact:

S. Varadaraj
Chief Financial Officer,
Godrej Agrovet Limited
Email: s.varadaraj@godrejagrovet.com
Tel No.: +91 22 2519 4864

Amit S Pendse
Head – Corporate Finance
Godrej Agrovet Limited
Email: gavlinvestors@godrejagrovet.com / amit.pendse@godrejagrovet.com
Tel No.: +91 22 2519 4488

Disclaimer: This communication is provided for information purposes only and does not constitute (and should not be construed as) an offer, invitation or solicitation to buy or sell any securities or other financial instruments, or any investment advice. Recipients should make their own independent assessment and consult appropriate professional advisers. The information and opinions contained herein are stated as of the date of this communication and are subject to change without notice; while reasonable care has been taken in its preparation, the Company makes no representation or warranty, express or implied, as to the accuracy, completeness or fairness of such information (including any third-party/industry data) and, to the fullest extent permitted by law, disclaims any liability for any loss arising from the use of this communication or its contents. Certain statements herein may constitute “forward-looking statements” under applicable laws and regulations, based on current expectations, assumptions and information available to the Company, and involve risks and uncertainties that could cause actual results to differ materially, including changes in economic and market conditions, competitive dynamics, laws, regulations, taxes and their interpretation, foreign exchange and interest rate movements, demand and supply conditions, operational or supply-chain disruptions, labour matters, litigation or regulatory proceedings, and the timing or impact of corporate actions. Forward-looking statements speak only as of the date hereof and undue reliance should not be placed on them;



except as required by law, the Company undertakes no obligation to update or revise them. This communication should be read together with the Company's disclosures and filings made from time to time in accordance with applicable legal and regulatory requirements; where alternative performance measures are included, they are presented for supplemental purposes, may not be comparable across companies, and should not be viewed as a substitute for financial information prepared in accordance with applicable accounting standards.